Enliven Therapeutics (NASDAQ:ELVN) Stock Keeps “Buy” Rating at Guggenheim

Enliven Therapeutics (NASDAQ:ELVN)‘s stock had its “buy” rating reaffirmed by equities research analysts at Guggenheim in a research report issued on Friday, Benzinga reports. They currently have a $78.00 price target on the stock. Guggenheim‘s price objective would suggest a potential upside of 60.13% from the stock’s previous close.

ELVN has been the subject of a number of other research reports. JPMorgan Chase & Co. began coverage on shares of Enliven Therapeutics in a research note on Thursday, October 1st. They set an “overweight” rating and a $75.00 target price for the company. HC Wainwright increased their price objective on Enliven Therapeutics from $65.00 to $73.00 and gave the stock a “buy” rating in a report on Monday, October 19th. Barclays began coverage on Enliven Therapeutics in a research report on Tuesday, August 18th. They set an “overweight” rating and a $78.00 price objective for the company. Wall Street Zen downgraded Enliven Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. Finally, Mizuho boosted their target price on Enliven Therapeutics from $62.00 to $73.00 and gave the company an “outperform” rating in a research note on Tuesday, August 18th. Ten investment analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Enliven Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $75.44.

Enliven Therapeutics Price Performance

ELVN traded up $3.92 on Friday, reaching $48.71. 236,893 shares of the company traded hands, compared to its average volume of 1,299,503. The stock’s 50 day moving average price is $47.48 and its 200-day moving average price is $42.96. Enliven Therapeutics has a 52-week low of $14.78 and a 52-week high of $62.32. The company has a market cap of $3.57 billion, a price-to-earnings ratio of -29.13 and a beta of 0.34.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings data on Thursday, November 5th. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.09. As a group, equities research analysts forecast that Enliven Therapeutics will post -1.79 earnings per share for the current fiscal year.

Insider Buying and Selling at Enliven Therapeutics

In other news, Director J. Scott Garland sold 13,000 shares of the firm’s stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $46.67, for a total transaction of $606,710.00. Following the transaction, the director owned 13,000 shares in the company, valued at approximately $606,710. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Benjamin Hohl sold 6,018 shares of Enliven Therapeutics stock in a transaction on Monday, October 19th. The shares were sold at an average price of $38.48, for a total transaction of $231,572.64. Following the completion of the sale, the chief financial officer directly owned 38,000 shares of the company’s stock, valued at approximately $1,462,240. The trade was a 13.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 31,054 shares of company stock worth $1,493,823. 3.00% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Enliven Therapeutics

Institutional investors have recently bought and sold shares of the stock. KBC Group NV acquired a new stake in shares of Enliven Therapeutics in the first quarter worth about $38,000. Three Bridge Wealth Advisors LLC acquired a new position in shares of Enliven Therapeutics during the 3rd quarter valued at about $53,000. Sterling Capital Management LLC increased its holdings in shares of Enliven Therapeutics by 1,180.7% during the 3rd quarter. Sterling Capital Management LLC now owns 1,921 shares of the company’s stock valued at $88,000 after acquiring an additional 1,771 shares during the last quarter. State of Wyoming acquired a new position in shares of Enliven Therapeutics during the 2nd quarter valued at about $96,000. Finally, ProShare Advisors LLC raised its stake in shares of Enliven Therapeutics by 29.5% in the 3rd quarter. ProShare Advisors LLC now owns 9,852 shares of the company’s stock valued at $452,000 after acquiring an additional 2,246 shares in the last quarter. 95.08% of the stock is currently owned by institutional investors.

About Enliven Therapeutics

Enliven Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with cancer. The company uses small-molecule drug discovery and development to pursue treatments designed to address validated cancer targets and improve patient outcomes.

Enliven’s pipeline includes ELVN-001, an investigational BCR-ABL1 tyrosine kinase inhibitor being developed for the treatment of chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor intended for use in patients with HER2-positive solid tumors.